The Oakland Convention Center hosted Psychedelic Science 2017, a six-day international conference that brought the modern psychedelic research revival into public view. The venue became a meeting place for scientists, underground guides, therapists, veteran psychonauts, funders, filmmakers, and entrepreneurs—and, especially through a prominent psychiatry panel, a stage for the field’s effort to gain institutional legitimacy without losing sight of its distinctive therapeutic challenges.

Conference Setting and Scale

In April 2017, the international psychedelic community gathered at the Oakland Convention Center for Psychedelic Science 2017, an every-few-years conference organized by the Multidisciplinary Association for Psychedelic Studies. Founded by Rick Doblin in 1986, the nonprofit had pursued the unlikely goal of restoring psychedelics to scientific and cultural respectability. By the time of the Oakland meeting, that effort had acquired new momentum: the Food and Drug Administration had approved Phase 3 trials of MDMA, while Psilocybin appeared close behind. Doblin had recently expressed astonishment at how quickly the field had advanced and how near victory seemed.

The gathering’s size marked a sharp change from the conference’s recent past. What had been a modest 2010 meeting of psychonauts and a handful of renegade researchers had become a six-day convention and conference attended by more than three thousand people from around the world. Researchers from twenty-five countries presented findings. Between lectures, panels, and plenaries, attendees moved through a sprawling marketplace of psychedelic books, artwork, and music. The Oakland venue thus contained both the formal ambitions of a scientific meeting and the broader public culture growing around psychedelic experience.

A Meeting Across Divides

The conference brought together groups that had often occupied different sides of the boundary between legitimate clinical practice and less formal or underground work. Scientists shared the gathering with guides and shamans, experienced psychonauts, therapists hoping to incorporate psychedelics into their practices, and people pursuing funding, filmmaking, or business opportunities. For the book’s narrator, the event also worked as a reunion: researchers interviewed during the reporting and several underground guides with whom the narrator had worked were present under one roof.

That mixture carried particular weight because psychedelic therapy had long unsettled psychiatric conventions. Its high-dose model envisioned a concentrated session aimed at profound change, rather than an extended course of weekly treatment, and asked clinicians to reconsider the customary roles of therapist and patient. The approach also relied on set and setting and gave spiritual experience a place in treatment. Earlier psychiatric models had been easier to fit within established accounts of mental illness or psychoanalysis; the newer therapeutic paradigm blurred lines between science and religion, sickness and health, and healer and sufferer. At the Oakland gathering, the presence of underground practitioners alongside academic and clinical researchers made that unresolved history part of the conference’s social fabric.

Psychiatry Takes the Stage

The most frequently recalled session was a plenary called Future of Psychedelic Psychiatry. Its panelists made the changing institutional climate unusually visible: Paul Summergrad, a former head of the American Psychiatric Association, sat alongside Tom Insel, former head of the National Institute of Mental Health. George Goldsmith, an American entrepreneur and health-industry consultant based in London, organized and moderated the discussion. Goldsmith and his wife, the Russian-born physician Ekaterina Malievskaia, had devoted substantial energy and resources to seeking approval for Psilocybin-assisted therapy in the European Union.

To the standing-room audience, the panel represented the mental-health establishment’s growing recognition of psychedelic therapy. Insel criticized the weak record of mental-health care compared with other areas of medicine, including its failure to reduce mortality from serious psychiatric disorders, and spoke of the promise of new treatment models. He valued the emphasis on psychotherapy alongside the drug, while warning that this approach could be difficult for regulators accustomed to evaluating medicines in isolation. The panel therefore offered recognition, but not an assurance that the existing regulatory framework could readily accommodate the treatment.

Promise and Caution

When Goldsmith asked what advice the researchers should take away, Insel urged them not to undermine the field’s prospects. He emphasized safety, scientific rigor, and reputational risk. Psychedelics, he suggested, might need to be presented differently in public and kept clearly apart from recreational use. He and Summergrad warned that one careless researcher or one patient’s disastrous experience could damage the prospects of the wider field. The caution carried an implicit historical shadow: the conference celebrated renewed legitimacy, but its participants knew that public trust could be lost as well as gained.

The overall mood in Oakland was celebratory, though attendees also voiced concern about the new attorney general’s efforts to revive the drug war. That coexistence of optimism and vigilance defined the venue’s significance in the account. The convention center was not presented as the source of psychedelic research or as a permanent institutional home; it was the temporary meeting place where a once-marginal movement could assemble at international scale, encounter senior psychiatric leaders, and confront the conditions on which wider acceptance might depend.